Triomics logo

Triomics

It builds oncology-specific AI software to help cancer centers apply artificial intelligence in cancer care workflows.

AI Healthcare
Oncology AI
Total Raised
$22M
Last Valuation
$147M
Headquarters
San Francisco, USA

Overview

Triomics develops oncology-specific AI for cancer centers, focusing on software tailored to the clinical and operational complexity of cancer care. Its target market is hospitals and cancer centers seeking AI systems built for oncology rather than generic healthcare workflows. The company’s positioning centers on a domain-specific approach to cancer care AI. Triomics raised a $22 million Series B on May 27, 2026, bringing disclosed funding to $22 million across one round.

Funding History

1 round · May 2026
$22M
Total Raised
1
Valuation: $147M
Cumulative: $22M

Triomics nabs $22M to bring oncology-specific AI to cancer centers

Investors not disclosed
Source

Frequently Asked Questions

How much has Triomics raised in total?
Triomics has raised a total of $22M across 1 funding round.
Who are Triomics's investors?
Triomics's investors include Undisclosed.
What does Triomics do?
Triomics develops oncology-specific AI for cancer centers, focusing on software tailored to the clinical and operational complexity of cancer care. Its target market is hospitals and cancer centers seeking AI systems built for oncology rather than generic healthcare workflows. The company’s positioning centers on a domain-specific approach to cancer care AI. Triomics raised a $22 million Series B on May 27, 2026, bringing disclosed funding to $22 million across one round.
Where is Triomics headquartered?
Triomics is headquartered in San Francisco, USA.